Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue
- PMID:6344147
- DOI:10.1016/0090-6980(83)90105-3
Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue
Abstract
The platelet anti-aggregating, cardiovascular and gastro-intestinal actions of a hydantoin prostaglandin analogue, BW245C have been compared with prostacyclin and PGD2 in several species. In human plasma in vitro, BW245C was 0.2 times as active as prostacyclin and 8 times as active as PGD2 in inhibiting platelet aggregation. In rat and rabbit plasma, BW245C was only weakly active but was more potent in sheep and horse plasma. Since the activity of PGD2 varied in a parallel fashion, BW245C may interact with PGD2 binding sites on platelets. The potency of BW245C as a vasodepressor also varied between species, being 0.5, 0.1, 0.06 and less than 0.02 times as active as prostacyclin in the anaesthetised dog, monkey, rat and rabbit respectively. The relative activity of BW245C as an inhibitor of platelet aggregation ex vivo was more comparable, being 0.08, 0.04 and 0.05 times as active as prostacyclin following intravenous infusion in the rabbit dog and monkey respectively. In the rabbit, BW245C was a highly selective platelet inhibitor with minimal cardiovascular actions, whereas in the dog and monkey, BW245C lowered BP in anti-aggregating doses. The potent platelet anti-aggregating actions of BW245C following parenteral or oral administration makes this hydantoin a potentially-useful anti-thrombotic prostaglandin analogue.
Similar articles
-
相互作用与环前列腺素,前列腺素D2carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.Br J Pharmacol. 1985 May;85(1):285-90. doi: 10.1111/j.1476-5381.1985.tb08858.x. Br J Pharmacol. 1985. PMID:2992652 Free PMC article.
-
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.Prostaglandins. 1978 Sep;16(3):373-88. doi: 10.1016/0090-6980(78)90216-2. Prostaglandins. 1978. PMID:364545
-
Different responsiveness of prostaglandin D2-sensitive systems to prostaglandin D2 and its analogues.Br J Pharmacol. 1985 Jun;85(2):367-75. doi: 10.1111/j.1476-5381.1985.tb08870.x. Br J Pharmacol. 1985. PMID:2992661 Free PMC article.
-
Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.Adv Exp Med Biol. 1985;192:109-25. doi: 10.1007/978-1-4615-9442-0_9. Adv Exp Med Biol. 1985. PMID:2871707 Review. No abstract available.
-
Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.Circulation. 1980 Dec;62(6 Pt 2):V19-25. Circulation. 1980. PMID:7002350 Review.
Cited by15articles
-
Role of the L-PGDS-PGD2-DP1 receptor axis in sleep regulation and neurologic outcomes.Sleep. 2019 Jun 11;42(6):zsz073. doi: 10.1093/sleep/zsz073. Sleep. 2019. PMID:30893431 Free PMC article. Review.
-
Putative role of prostaglandin receptor in intracerebral hemorrhage.Front Neurol. 2012 Oct 22;3:145. doi: 10.3389/fneur.2012.00145. eCollection 2012. Front Neurol. 2012. PMID:23097645 Free PMC article.
-
Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice.Age (Dordr). 2010 Sep;32(3):271-82. doi: 10.1007/s11357-010-9135-y. Epub 2010 Mar 5. Age (Dordr). 2010. PMID:20640551 Free PMC article.
-
The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses.Br J Pharmacol. 2008 Mar;153 Suppl 1(Suppl 1):S191-9. doi: 10.1038/sj.bjp.0707488. Epub 2007 Oct 29. Br J Pharmacol. 2008. PMID:17965752 Free PMC article. Review.
-
PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury.Eur J Neurosci. 2007 Jul;26(1):73-8. doi: 10.1111/j.1460-9568.2007.05627.x. Epub 2007 Jun 16. Eur J Neurosci. 2007. PMID:17573924 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases